Subject Index

acetic acid-induced writhing (AAW) test, 4
adenylate cyclase, 196
  effect of repeated ECS on, 154
  effect of chronic anti-depressants, 148
  response to forskolin and Gpp(NH)p, 148
agonists affinity for D_1 receptor
  effect of chronic anti-depressants, 162
agonists affinity for D_2 receptors
  effect of chronic anti-depressants, 162
alpha-1 adrenergic blockers
  effect of anti-immobility effect of anti-depressants, 69
alpha-2 adrenergic receptors
  anti-immobility effect of antidepressants, 69
amineptine
  anti-immobility effect, 64
amitriptyline, 1
  anti-immobility effect, 64
  anticholinergic effects, 180
amphetamine, 31
  reward, 31, 57
    -induced locomotor activity, 140
    -induced stereotypy, 142
anhedonia, 42
  symptom of depression, 110
    -induced by DA antagonists, 78
animal model
  for post-cocaine depression, 42
  of disrupted social skill, 83
  of depression, 42
antidepressants,
  effect of chronic treatment on meso-limbic DA system, 58, 59, 78
  effect of chronic treatment on amphetamine-induced locomotor activity, 140
  effect of chronic treatment on DA autoreceptors

sensitivity, 59, 102, 123
and monoamine uptake, 77
effect of chronic treatment on postsynaptic DA receptors sensitivity, 80, 123
effect of chronic treatment on receptor function, 78
chronic treatment and down-regulation of beta-adrenoceptors, 92, 122
effect of chronic treatment on NA receptors, 122
effect of chronic treatment on SE receptors, 122
effect on stress-induced anhedonia, 79
long-term effects, 121
apomorphine, 10, 13
antipsychotic effect, 188
effect on firing rate of DA neurons, 114, 117
-induced stereotypy, 142
aversion, 34

behavioural supersensitivity studies, 11
benzazepine, 1
beta-adrenergic receptors
anti-immobility effect, 69
125I-iodocyanopindolol (ICYP) binding, 197
biochemical correlates of DA mediated behaviour, 17
bromocriptine, 44, 45
bupropion
anti-immobility effect, 67

chlorimipramine
clinical effect, 177
chronic antidepressants
and dopamine receptors up-regulation, 144
and LY 171555-induced locomotor activity, 128
effect on behavioural response to DA agonists, 122
chronic haloperidol
and B-HT 920-induced locomotor activity, 133
-induced hypersensitivity of DA receptors, 177
chronic mild stress model, 83
chronic stress model, 85
chronic unpredictable stress (CUS) procedure, 91, 92
cooperative behaviour, 77
cocaine, 32
reward, 32, 57
self-administration, neuro-chemical substrate, 40
withdrawal in humans, 42
post-cocaine depression, 42, 45
post-cocaine withdrawal symptoms, 44
rewarding properties of, 45
corticosterone
quinpirole-induced increase, 143

D_1 agonists
CY 208–243, 14
SKF 38393, 9, 10, 14
-induced grooming, 15, 142
D_1 and D_2 receptors
distribution in brain, 10
D_1 antagonists, 1
D_1:D_2 receptors ratio, 16
D_2 agonists

N-0437, 14
quinpirole, 14, 16
quinpirole-induced locomotor activity, 142
quinpirole-induced stereotypic behaviour, 15, 127
3H-DA uptake
effect of imipramine and desipramine, 153
DA and depression, 188
human studies, 177
DA autoreceptors
functional role, 111
DA metabolism
effect of chronic imipramine, 153
DA receptors classification, 122, 193, 194
DA uptake selective inhibitors
GBR-12935, GBR-12909, GBR-12783, LR 5182, BTCP, 168
DA-stimulated adenylate cyclase
effect of chronic imipramine, 150
DA-uptake, 101
DA-uptake inhibitors, 103
nomifensine, bupropion, GBR 12909, 101
depression, 1
DSM-III criteria for, 178
Hamiltion Psychiatric Rating Scale for, 178
desipramine, 44, 45, 58
anti-immobility effect, 64, 65
despair test (DT), 91, 92
dopaminergic agonists
anti-immobility effect, 68
down-regulation, 9, 13
of D_2 receptors, 9, 17
of beta-adrenoceptors, 92
of rotational behaviour, 14
drug abuse and dependence, 34, 39
drug dependence
role of the nucleus accumbens, 39

electroshock therapy
effect on DA autoreceptor sensitivity, 113
anti-immobility effect, 66
ethanol, 32

forced swimming test, 63
forskolin-stimulated adenylate cyclase,
effect of chronic imipramine, 151

GBR 12909
and DA-uptake, 102
clinical effects, 105
effect on ICSS response, 54

heroin
reward, 46
self-administration, 46
6-hydroxydopamine (–)OHDA) lesions, 53
6-OHDA in the nucleus accumbens
effect on cocaine self-administration, 56

imipramine, 77
anti-immobility effect, 66
effect of chronic treatment on D_2 agonists response, 123
effect of chronic treatment

on dopaminergic receptor sensitivity, 115
effect of chronic treatment on B-HT 920-induced sedation, 131
effect chronic treatment on behavioural responses to SKF 38393, 132
effect chronic treatment on LY 171555-induced hypomotility, 124
effect chronic treatment on LY 171555-induced locomotor activity, 125
effect chronic treatment on LY 171555-induced stereotypy, 126
effect chronic treatment on V_{max} of adenylate cyclase, 135
incentive, 27
intracranial self-stimulation (ICSS), 43, 51, 52
of the VTA, 53
effect of desipramine, 58
intravenous self-administration, 40, 51
in vivo voltammetry, 51
iprindole
anti-immobility effect, 66

learning, 27
l-sulpiride
and apomorphine-induced stereotypy, 187
and D_1–D_2 receptors associated adenylate cyclase, 195
and DA synthesis and metabolism, 187
and depression, 177
and firing rate of DA neurons, 187
and LY 171555-induced locomotor activity, 129
and presynaptic D_2 receptors, 185, 187, 189
and sedative effect of apomorphine, 187
and tyrosine hydroxylase, 187
antagonism of anti-immobility effect of antidepressants, 68
antidepressant action of low doses of, 102, 180, 181, 185, 186
antipsychotic effect, 185
blockade of DA auto-receptors, 185
blockade of D_2 receptors, 186
effect of chronic treatment on 125I-ICYP binding, 197
effect of chronic treatment on bromocriptine inhibited adenylate cyclase, 196
effect of chronic treatment on D_1 receptor-associated adenylate cyclase, 196
long-term treatment and DA receptors response, 194
mechanism of anti-depressive action of, 185
side effects, 180
therapeutic effects, 185
lithium
and adenylate cyclase activity, 135

mesolimbic DA system
and anti-immobility effect of antidepressants, 68
mianserine,
anti-immobility effect, 67
microdyalisis, 28
MIF-1
anti-immobility effect, 70
moclobemide
and apomorphine-induced sedation, 141
molecular biological correlates of DA-mediated behaviour, 17
monoaminergic transporter regulation, 173
morphine, 32
motivation, 31
neural circuitry, 51
mRNA
distribution of D_2 receptors mRNA in brain, 18
for the D_2 dopamine receptors, 9
hybridization studies, 11
regulation of D_2 receptor mRNA, 20
muricide test, 5

neuroleptics
and depression, 102, 189
and mania, 102
nomifensine
anti-immobility effect, 67
noradrenaline uptake selective inhibitors
desipramine, maprotiline, 168
nortriptyline
anti-immobility effect, 67

opiate
dependence, neuro-anatomical substrate, 46
withdrawal: a role for nucleus accumbens, 46, 47

pargyline
anti-immobility effect, 67
Parkinson's disease and depression, 102
3H-paroxetine binding, 169
pentylentetrazol-induced seizures in mice, 2
perphenazine, 1
place-preference, 32, 33
presynaptic receptor sensitivity and anti-depressant therapies, 112
Prolactin (PRL)
"antidepressive" effect, role of DA, 95
behavioural effects, role of DA neurotransmission, 93
effect on model of depression, 91
receptor binding studies, 11
reinforcement, 27, 51, 52
REM sleep deprivation
anti-immobility effect, 67
reserpine
and depression, 189
and LY 171555-induced locomotor activity, 131
-induced immobility, 102
reward, 27, 51, 52, 77
neural circuitry, 57
role of DA, 78
brain reward system, 39

3H-SCH 23390 binding,
effect of chronic antidepressants, 154, 160
effect of chronic imipramine, 150
SCH 23390, 1
and LY 171555-induced locomotor activity, 129
social cooperation model, 85
social isolation, 77
sodium-coupled 5-HT transporter, 169
purification, 170
sodium-coupled DA transporter, 171
sodium-coupled monoaminergic transport systems, 167
sodium-coupled NA transporter, 173
3H-spiperone binding
effect of chronic antidepressants, 161
stress, 63, 77
-induced anhedonia, 79, 85
swimming test, 5

TBZ test, 5
thyreotropin-releasing hormone (TRH)
effect on models of depression, 91
"antidepressive" effect, role of DA, 95
behavioural effect, role of DA neurotransmission, 93
receptors, 92
tricyclic antidepressants, 1, 77

up-regulation, 9, 10
or postsynaptic DA receptors, 13
5-HT uptake inhibitor binding sites, 169
topography, 169
5-HT uptake selective inhibitors, 168
citalopram, indalpine, SL 81.0385, fluoxetine, fluvoxamine, paroxetine

Vogel conflict test in rats, 3, 4

withdrawal
from chronic amphetamine and ICSS response rate, 58
from cocaine in humans, 42